Risk Factors Update Summary
- Received a Complete Response Letter (CRL) from the FDA for omecamtiv mecarbil, impacting potential sales.
- Discontinued Phase 3 clinical trial of reldesemtiv in ALS due to futility, affecting development.
- Potential dependency on Microgenics for manufacturing immunoassay for omecamtiv mecarbil in key markets.
- Counterparty risk under loan agreements with RPDF and RPI ICAV, impacting financial stability.
- Increased emphasis on cost containment may affect commercial success and pricing strategies.
- Uncertainty regarding the implementation of drug importation programs and their impact on prices.
- Executive order directing HHS to test new models for lowering drug costs, impact on pricing strategies.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1061983&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.